|Type||Public (LSE: VEC)|
|Key people||Jack Cashman, Chairman
Christopher Blackwell, (CEO)
|Revenue||£25.2 million (2008)|
|Operating income||£(25.1) million (2008)|
|Net income||£(19.2) million (2008)|
Vectura was formed in 1997 with venture finance backing. In 1999 it acquired Co-ordinated Drug Development and the Centre for Drug Formulation Studies. In 2002 it acquired inhaler technology and an associated engineering team from Cambridge Consultants.
In 2004 it was listed on the Alternative Investment Market. In 2007 it acquired Innovata plc, a developer of pulmonary products, and then moved on the full list of the London Stock Exchange.
The Group specialises in inhalation technology and currently has two main focuses:
- Respiratory: inhaled products for asthma and COPD
- Neurology: products for Parkinson's Disease and migraine
- Official site
- Vectura boosted by deal with GSK worth over $30 million upfront plus royalties The Pharma Letter,6th August, 2010